Skip to main content

Table 2 Severity and prevalence of symptoms at D28+ survey (N = 411)

From: COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Symptom

Mild

Moderate

Severe

Overall prevalence*

Cough

20.4%

7.8%

1.2%

29.4%

Headache

17.3%

9.0%

1.7%

28.0%

Myalgia

15.3%

8.8%

1.9%

26.0%

Anosmia

20.2%

NA

3.4%

23.6%

Dyspnea

14.6%

7.8%

0.7%

23.1%

Post-exertion polypnea

12.7%

7.4%

1.0%

21.1%

Ageusia

18.0%

NA

2.2%

20.2%

Cognitive disturbances

11.2%

6.6%

1.7%

19.5%

Chest pain/tightness

12.4%

4.4%

0.7%

17.5%

Arthralgia

7.1%

6.1%

2.0%

15.1%

Hair loss

6.6%

5.1%

2.4%

14.1%

Palpitations

6.3%

5.1%

0.7%

12.2%

Nausea

6.1%

3.2%

2.2%

11.4%

Diaphoresis

4.6%

3.4%

2.7%

10.7%

Rhinorrhea

8.0%

2.2%

0.2%

10.5%

Pharyngitis

7.5%

1.5%

0.5%

9.5%

Ear pain

6.6%

2.2%

0.7%

9.5%

Diarrhea

3.7%

2.2%

2.4%

8.3%

Rash

3.9%

2.0%

0.5%

6.3%

Chills/shivering

4.6%

1.2%

0.2%

6.1%

Need for oxygen

2.4%

2.4%

1.0%

5.9%

Loss of hearing

4.0%

NA

0.0%

4.0%

Fever

2.4%

0.2%

0.5%

3.2%

Vomiting

1.9%

0.0%

0.5%

2.4%

Thromboembolism

0.5%

1.0%

0.2%

1.7%

CKD

0.7%

0.2%

0.2%

1.2%

  1. For diarrhea and vomiting, 1–2 was classified as mild, 3–4 as moderate, and 5 or more as severe. For loss of hearing, smell, and taste, “same as usual” was considered none, “less than usual” was considered mild, and “no sense” was considered severe
  2. CKD chronic kidney disease, NA not applicable
  3. *Overall prevalence represents the sum of mild, moderate, and severe categories